Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Introduction</h3><p>A series of randomized controlled trials have investigated different first-line immunotherapy combinations, but the optimal combination strategy is yet to be established.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We performed a systematic review and Bayesian network meta-analysis by retrieving relevant literature from PubMed, Embase, the Cochrane library, the <a href="http://ClinicalTrials.gov">ClinicalTrials.gov</a>, and the major international conferences. We included published and grey sources of randomized clinical trials comparing immunotherapy combinations with other treatments for advanced non-small-cell lung carcinoma (NSCLC) patients as first-line treatments. This study was registered in the Prospective Register of Systematic Reviews (CRD42020210501) to ensure transparency.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>We analyzed 16 studies involving 8,278 patients, including 10 immunotherapy combinations. For patients without programmed death-ligand 1 (PD-L1) selection, pembrolizumab plus chemotherapy was shown to be comparable to sintilimab plus chemotherapy in providing the best overall survival (OS) benefit (HR: 0.96, 95% CI: 0.72–1.29). Furthermore, atezolizumab plus bevacizumab plus chemotherapy appeared to provide the best progression-free survival (PFS, HR: 0.45, 95% CI: 0.36–0.55) as well as the best objective response rate (ORR, OR: 0.23, 95% CI: 0.12–0.42). Subgroup analysis by PD-L1 suggested that nivolumab plus ipilimumab plus chemotherapy was associated with the best OS in patients with PD-L1 <1% and that pembrolizumab plus chemotherapy was associated with the best OS in patients with PD-L1 ≥1%. Pembrolizumab and sintilimab were associated with relatively fewer grade ≥3 adverse events when compared with other immunotherapies combined with chemotherapy.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Our results suggest that anti-programmed death-1 combinations are associated with potentially higher survival outcomes than anti-PD-L1 combinations with comparable safety profiles. Moreover, pem-chemo and nivo-ipi-chemo appear to be superior first-line immunotherapy combinations for advanced NSCLC patients with positive and negative PD-L1 expression, respectively. Although atezo-beva-chemo treatment provided the best PFS and ORR, the addition of chemotherapy to immunotherapy would increase the toxicity, especially when anti-angiogenesis drugs are simultaneously added.</p>

First‐line PD ‐1/ PD‐L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non‐squamous non‐small cell lung cancer: A Bayesian network meta‐analysis of randomized controlled trials

Frontline Anti-Pd-1/pd-l1 Versus Bevacizumab in Advanced Non-Small-cell Lung Cancer: a Network Meta-Analysis

First-Line Treatment Options For Pd-L1-Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis

PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials

First-line CDK4/6 inhibitor-based combinations for HR+/HER2-advanced breast cancer: A Bayesian network meta-analysis

Efficacy and safety of anti ‐PD ‐1/ PD‐L1 in combination with chemotherapy or not as first‐line treatment for advanced non‐small cell lung cancer: A systematic review and network meta‐analysis

Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis.

Immunotherapy Combined with Chemotherapy Versus Chemotherapy Alone As the First‐line Treatment of PD‐L1‐negative and Driver‐gene‐negative Advanced Nonsquamous Non‐small‐cell Lung Cancer: an Updated Systematic Review and Meta‐analysis

PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study

Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations

Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis

PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data

Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis

P2.01-030 Real World Study of Bevacizumab-Contained Regimen As First Line Therapy in Chinese Patients with Advanced NSCLC

The Optimal Timing And Courses Of Bevacizumab Added To Chemotherapy For Non-Squamous Non-Small Cell Lung Cancer: Revelations From The Real-World Experience In A Single Chinese Cancer Center

Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis

Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis

The efficacy of bevacizumab combined with platinum-containing chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review and meta-analysis of randomized clinical trials

First-line Pemetrexed-Platinum Doublet Chemotherapy with or Without Bevacizumab in Non-Squamous Non-Small Cell Lung Cancer: A Real-World Propensity Score-Matched Study in China

Randomized Clinical Trial of Pembrolizumab Vs Chemotherapy for Previously Untreated Chinese Patients with PD‐L1‐positive Locally Advanced or Metastatic Non–small‐cell Lung Cancer: KEYNOTE‐042 China Study

Pembrolizumab or Bevacizumab Plus Chemotherapy As First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study.